Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceyesto is a brand of melatonin, a naturally occurring hormone produced by the pineal gland that regulates the sleep-wake cycle (circadian rhythm). Developed by ALTURiX, Ceyesto is available as an immediate-release 3 mg tablet and a 1 mg/ml oral solution. It is indicated for the short-term treatment of jet lag in adults, and for the treatment of insomnia in children and adolescents aged 6 to 17 years with Attention Deficit Hyperactivity Disorder (ADHD) where sleep hygiene measures have been insufficient. The oral solution is also indicated for delayed sleep-wake phase disorder (DSWPD) in individuals aged 6 to 25 years, and for short-term sedation to facilitate electroencephalograms (EEGs) in children and adolescents aged 1 to 18 years. Melatonin acts as an agonist at melatonin receptors MT1 and MT2 in the brain to promote sleep.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on melatonin (Alturix).